Marvel drug for infertility!!

Abstract

: Comparative study of Dydrogesterone versus oral sustained release micronized hydroxy-progesterone for support of luteal phase.: A randomized controlled trial, performed from March 2022 to April 2023. 200 women between 18–40 years of age attending infertility OPD at Gandhi hospital were enrolled in this study. Subjects were randomized and were given either oral dydrogesterone or oral sustained release micronized hydroxy-progesterone. Statistical analysis was done accordingly.In the present study, oral dydrogesterone was demonstrated to be superior than sustained release micronized hydroxy-progesterone, with UPT positive rates being 83% and 30% respectively. Dydrogesterone given orally was tolerated well with similar safety profile to sustained release micronized hydroxy-progesterone.Our study results depicted the use of dydrogesterone to be effective when compared to oral sustained release micronized hydroxy-progesterone in terms of luteal phase support. Dydrogesterone is hailed to be superior in regards of positive pregnancy rates in the current study.